WallStSmart

Monster Beverage Corp (MNST)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Monster Beverage Corp generates 50% more annual revenue ($8.29B vs $5.54B). RMD leads profitability with a 27.4% profit margin vs 23.0%. RMD appears more attractively valued with a PEG of 1.23. RMD earns a higher WallStSmart Score of 73/100 (B).

MNST

Strong Buy

68

out of 100

Grade: B-

Growth: 8.0Profit: 9.5Value: 6.0Quality: 7.8
Piotroski: 5/9Altman Z: 5.91

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 5.3Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MNSTUndervalued (+70.6%)

Margin of Safety

+70.6%

Fair Value

$274.97

Current Price

$86.29

$188.68 discount

UndervaluedFair: $274.97Overvalued
RMDOvervalued (-13.1%)

Margin of Safety

-13.1%

Fair Value

$229.58

Current Price

$206.76

$22.82 premium

UndervaluedFair: $229.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MNST6 strengths · Avg: 9.5/10
Operating MarginProfitability
31.3%10/10

Strong operational efficiency at 31.3%

EPS GrowthGrowth
66.6%10/10

Earnings expanding 66.6% YoY

Altman Z-ScoreHealth
5.9110/10

Safe zone — low bankruptcy risk

Market CapQuality
$84.38B9/10

Large-cap with strong market position

Return on EquityProfitability
26.8%9/10

Every $100 of equity generates 27 in profit

Profit MarginProfitability
23.0%9/10

Keeps 23 of every $100 in revenue as profit

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.3%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

Areas to Watch

MNST3 concerns · Avg: 3.3/10
PEG RatioValuation
2.234/10

Expensive relative to growth rate

Price/BookValuation
10.2x4/10

Trading at 10.2x book value

P/E RatioValuation
41.7x2/10

Premium valuation, high expectations priced in

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : MNST

The strongest argument for MNST centers on Operating Margin, EPS Growth, Altman Z-Score. Profitability is solid with margins at 23.0% and operating margin at 31.3%. Revenue growth of 17.6% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bear Case : MNST

The primary concerns for MNST are PEG Ratio, Price/Book, P/E Ratio. A P/E of 41.7x leaves little room for execution misses.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

MNST profiles as a growth stock while RMD is a mature play — different risk/reward profiles.

RMD carries more volatility with a beta of 0.84 — expect wider price swings.

MNST is growing revenue faster at 17.6% — sustainability is the question.

MNST generates stronger free cash flow (584M), providing more financial flexibility.

Bottom Line

RMD scores higher overall (73/100 vs 68/100), backed by strong 27.4% margins and 10.8% revenue growth. MNST offers better value entry with a 70.6% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Monster Beverage Corp

CONSUMER DEFENSIVE · BEVERAGES - NON-ALCOHOLIC · USA

Monster Beverage Corporation is an American beverage company that manufactures energy drinks including Monster Energy, Relentless and Burn.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?